SYNVISC ONE®

Product Information

• Active ingredient: Hylan G-F 20
• Strength: 6 ml (48 mg) hylan G-F 20
• Package content: 1 x 10 ml pre-filled syringe
• Manufacturer: Sanofi Genzyme
• Brand: SYNVISC®
• Category: Orthopedic Injections

SYNVISC-One® is a single-dose hyaluronic acid injection designed to provide long-lasting relief from knee osteoarthritis pain. It works by restoring joint lubrication and cushioning, reducing discomfort, and improving mobility. This non-surgical treatment helps patients maintain an active lifestyle with up to six months of pain relief.

Key Uses of Synvisc One

Synvisc One is formulated to alleviate pain caused by osteoarthritis, especially in the knee joints. The treatment is ideal for patients who do not benefit from oral pain medications, mobility aids, supplements, and other non-pharmacological therapies.

Manufacturing Information for Synvisc One

Synvisc One is produced by Genzyme, a Sanofi company. Registered healthcare professionals can order Synvisc products at the Kinami Health online store.

Expected Benefits and Results of the Treatment

The use of Synvisc One brings the following benefits:

• Alleviated knee pain.
• Improved joint function.
• Long-lasting results.
• Convenient administration.

Synvisc One Key Ingredients and Device Features

Synvisc One combines carefully selected ingredients, as follows:

• Hydrated hylan A and B polymers (animal-derived, sourced from rooster combs, and chemically crosslinked to increase viscosity and elasticity).
• Sodium chloride
• Disodium hydrogen phosphate
• Water for injection

Included Items or Accessories

Each box contains:

• 1 x 10 ml pre-filled syringe for single use.
• Traceability labels
• Product pamphlet

Administration Method for Synvisc One

Synvisc One should be administered by a trained healthcare professional.

Preparation:

• Examine the affected joint and obtain the patient’s medical history.
• Disinfect the treatment area.

Injection:

• Twist the cap of the syringe to minimise product leakage.
• Attach the appropriate-sized needle.
• Apply the gel to the damaged synovial cavity.
• The entire 6 ml syringe is the recommended dosage for a knee joint in one session.

Guidelines for Proper Aftercare

For best results, patients would adhere to these post-treatment guidelines:

• Avoid strenuous physical activity in the next 48 hours.

Duration of Synvisc One Effects

The results of Synvisc One can last up to 6 months, until the hylan gel is metabolised by the body. The duration of the effects depends on individual needs and each person’s current health condition.

Potential Risks and Side Effects

Synvisc One is generally well-tolerated by patients, but users should be aware of potential reactions.

Common side effects:

• Pain and redness at the injection site.
• Heat sensation.
• Fluid accumulation at the injection site.

All these reactions are mild and temporary, and can be treated with cold compresses.

Rare reactions:

• Rash, muscle pain, and headaches.
• Fever, dizziness, and nausea
• Swollen face and mouth.

Synvisc One Treatment Contraindications

Synvisc One is not suitable for these groups of patients:

• Women who are pregnant or lactating.
• Pediatric patients.
• Individuals with hypersensitivity or allergies to hyaluronic acid or sodium hyaluronate products.
• Patients with joint infections or skin diseases at the injection site.

Practices to avoid:

• Injecting the product into blood vessels, synovial tissues or outside the joint space.

Buying SYNVISC-ONE® in Canada

Kinami Health supplies genuine SYNVISC-ONE® to licensed healthcare professionals and clinics across Canada, sourced through verified channels and delivered in sealed original packaging with a traceable LOT number, with wholesale pricing and fast delivery.

In Canada, who may administer intra-articular injections varies by province and professional college; practitioners should follow the rules that apply in their own jurisdiction. Adverse reactions can be reported to Health Canada.

Explore the full SYNVISC® range or compare other products in the Orthopedic Injections category.